The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro
Role of baseline HIV-1 RT polymorphisms on response to TDF + FTC-based HAART was defined. A98S mutation increased virological success at Week 24 of treatment. In vitro and structural data support that A98S increased susceptibility to TDF and FTC. These findings may help clinicians in the selection of the optimal NRTI backbone.